Generation of anti-TLR2 intrabody mediating inhibition of macrophage surface TLR2 expression and TLR2-driven cell activation.
BACKGROUND
Toll-like receptor (TLR) 2 is a component of the innate immune system and senses specific pathogen associated molecular patterns (PAMPs) of both microbial and viral origin. Cell activation via TLR2 and other pattern recognition receptors (PRRs) contributes to sepsis pathology and chronic inflammation both relying on overamplification of an immune response. Intracellular antibodies expressed and retained inside the endoplasmatic reticulum (ER-intrabodies) are applied to block translocation of secreted and cell surface molecules from the ER to the cell surface resulting in functional inhibition of the target protein. Here we describe generation and application of a functional anti-TLR2 ER intrabody (alphaT2ib) which was generated from an antagonistic monoclonal antibody (mAb) towards human and murine TLR2 (T2.5) to inhibit the function of TLR2. alphaT2ib is a scFv fragment comprising the variable domain of the heavy chain and the variable domain of the light chain of mAb T2.5 linked together by a synthetic (Gly4Ser)3 amino acid sequence.


RESULTS
Coexpression of alphaT2ib and mouse TLR2 in HEK293 cells led to efficient retention and accumulation of TLR2 inside the ER compartment. Co-immunoprecipitation of human TLR2 with alphaT2ib indicated interaction of alphaT2ib with its cognate antigen within cells. alphaT2ib inhibited NF-kappaB driven reporter gene activation via TLR2 but not through TLR3, TLR4, or TLR9 if coexpressed in HEK293 cells. Co-transfection of human TLR2 with increasing amounts of the expression plasmid encoding alphaT2ib into HEK293 cells demonstrated high efficiency of the TLR2-alphaT2ib interaction. The alphaT2ib open reading frame was integrated into an adenoviral cosmid vector for production of recombinant adenovirus (AdV)-alphaT2ib. Transduction with AdValphaT2ib specifically inhibited TLR2 surface expression of murine RAW264.7 and primary macrophages derived from bone marrow (BMM). Furthermore, TLR2 activation dependent TNFalpha mRNA accumulation, as well as TNFalpha translation and release by macrophages were largely abrogated upon transduction of alphaT2ib. alphaT2ib was expressed in BMM and splenocytes over 6 days upon systemic infection with AdValphaT2ib. Systemic transduction applying AdValphaT2ib rendered immune cells largely non-responsive to tripalmitoyl-peptide challenge. Our results show persistent paralysis of TLR2 activity and thus inhibition of immune activation.


CONCLUSIONS
The generated anti-TLR2 scFv intrabody inhibits specifically and very efficiently TLR2 ligand-driven cell activation in vitro and ex vivo. This indicates a therapeutic potential of alphaT2ib in microbial or viral infections.
Kirschning
Carsten J
CJ
Institute of Medical Microbiology, University Duisburg-Essen, D-45122 Essen, Germany.
Dreher
Stefan
S
Maass
Björn
B
Fichte
Sylvia
S
Schade
Jutta
J
Köster
Mario
M
Noack
Andreas
A
Lindenmaier
Werner
W
Wagner
Hermann
H
Böldicke
Thomas
T
D000256:Adenoviridae; D000595:Amino Acid Sequence; D000818:Animals; D000911:Antibodies, Monoclonal / Q000096:biosynthesis* / Q000276:immunology; D000918:Antibody Specificity; D001483:Base Sequence; D002460:Cell Line; D004721:Endoplasmic Reticulum / Q000378:metabolism; D005822:Genetic Vectors; D006801:Humans; D015850:Interleukin-6 / Q000032:analysis; D008264:Macrophages / Q000378:metabolism*; D051379:Mice; D008810:Mice, Inbred C57BL; D008969:Molecular Sequence Data; D015398:Signal Transduction; D057127:Single-Chain Antibodies / Q000096:biosynthesis* / Q000276:immunology; D051195:Toll-Like Receptor 2 / Q000276:immunology / Q000378:metabolism*; D014162:Transfection; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis
D000911:Antibodies, Monoclonal; D015850:Interleukin-6; D057127:Single-Chain Antibodies; D051195:Toll-Like Receptor 2; D014409:Tumor Necrosis Factor-alpha
J Clin Invest. 2004 May;113(10):1473-81
15146245
Curr Gene Ther. 2004 Mar;4(1):1-14
15032610
Methods. 2004 Oct;34(2):240-9
15312677
J Biol Chem. 2007 May 4;282(18):13190-8
17353199
Nat Rev Genet. 2003 May;4(5):346-58
12728277
J Biol Chem. 2003 Oct 10;278(41):39822-9
12860988
Gene Ther. 2006 Oct;13(20):1480-92
16738691
J Immunol Methods. 2009 Feb 28;341(1-2):30-40
19038261
Cancer Res. 2005 Feb 1;65(3):972-81
15705898
Proc Natl Acad Sci U S A. 2000 Oct 24;97(22):12266-71
11050246
J Immunol Methods. 2005 May;300(1-2):146-59
15946674
Curr Opin Biotechnol. 2001 Oct;12(5):461-6
11604321
Gene Ther. 2004 Apr;11(7):581-90
14973543
Traffic. 2004 Feb;5(2):89-101
14690498
Immunol Rev. 2004 Dec;202:250-65
15546398
Mol Ther. 2007 Feb;15(2):378-85
17235317
Nat Cell Biol. 2005 Aug;7(8):766-72
16056268
Hum Gene Ther. 1998 Mar 1;9(4):487-96
9525310
Am J Respir Cell Mol Biol. 1999 Mar;20(3):361-70
10030833
Proc Natl Acad Sci U S A. 1995 Apr 11;92(8):3137-41
7724529
Nature. 2009 Jan 1;457(7225):102-6
19122641
Ann Clin Lab Sci. 2005 Summer;35(3):227-9
16081577
Cell. 1992 Jan 24;68(2):353-64
1310258
Cell. 1997 Oct 31;91(3):295-8
9363937
J Cell Biochem. 2005 Jul 1;95(4):827-39
15838884
Mol Pharm. 2009 Mar-Apr;6(2):366-74
19227971
BMC Biotechnol. 2008 Jan 29;8:5
18226275
Drugs. 2006;66(1):15-29
16398566
Biochim Biophys Acta. 2002 May 3;1575(1-3):15-25
12020814
Nat Med. 2005 Mar;11(3):263-70
15723075
J Gene Med. 2003 Jun;5(6):451-62
12797110
Lancet. 2005 Jan 1-7;365(9453):63-78
15639681
Am J Pathol. 2003 Apr;162(4):1221-7
12651614
Mol Ther. 2003 Sep;8(3):355-66
12946308
Oncogene. 1999 Jan 14;18(2):551-7
9927212
Stem Cells. 2001;19(1):24-36
11209088
Biochem J. 2005 May 1;387(Pt 3):897-903
15610068
J Biol Chem. 2003 Nov 28;278(48):47812-9
12947084
Nat Med. 2007 May;13(5):552-9
17479101
Expert Opin Biol Ther. 2006 Mar;6(3):203-14
16503731
J Cell Mol Med. 2007 Jan-Feb;11(1):54-70
17367501
Crit Rev Biochem Mol Biol. 2005 Jul-Aug;40(4):191-228
16126486
Proc Natl Acad Sci U S A. 1998 Nov 10;95(23):13875-80
9811894
Mol Biotechnol. 1995 Jun;3(3):207-20
7552690